The biological and diagnostic roles of MicroRNAs in meningiomas

Wang, Lei; Chen, Shengpan; Ling, Yan; Zhang, Hongqi; Ren, Nianjun; Ma, Ruoyu; He, Zhengwen

doi:10.1515/revneuro-2020-0023

Cited by 18 publications

(18 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In meningiomas, microRNA biomarkers in serum could be developed as a convenient and effective indicator to diagnose and monitor meningioma's; our results demonstrate that miR-181d is a promising candidate. Little studies have demonstrated a plasmatic profile of microRNA expression in patients with meningiomas, evidencing eventual usefulness for tracking and monitoring these patients [23,24] Lakomy et al [25] analyzed 38 samples of patients diagnosed with glioblastomas who presented 32% methylation of MGMT by real-time PCR. High expression of miR-21 and miR-181c was also observed, and this high expression was associated with early progression.…”

Section: Discussionmentioning

confidence: 99%

“…In meningiomas, microRNA biomarkers in serum could be developed as a convenient and effective indicator to diagnose and monitor meningioma’s; our results demonstrate that miR-181d is a promising candidate. Little studies have demonstrated a plasmatic profile of microRNA expression in patients with meningiomas, evidencing eventual usefulness for tracking and monitoring these patients [ 23 , 24 ]…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Role of MicroRNA 181d as a Possible Biomarker Associated With Tumor Progression in Meningiomas

Carneiro¹,

Cirino²,

Panepucci³

et al. 2021

Cureus

View full text Add to dashboard Cite

Introduction Meningiomas are slow-growing intracranial neoplasms that originate from arachnoid meningothelial cells and represent 13-26% of intracranial tumors, thus being the most common. There are numerous technological advances available for a better understanding of the molecular pathways correlated with tumorigenesis and tumor progression of meningiomas. In this context, the role of microRNAs (miRNAs), which are non-coding RNAs (ncRNAs) consisting of 18 to 25 nucleotides whose function is the silencing of mRNA at the posttranscriptional level, has been highlighted. Recent studies suggest that miRNAs may act as possible biomarkers as well as therapeutic targets for various diseases, including brain tumors. Therefore, the objective of our study was to evaluate the tissue and plasma expression of the miRNAs miR-181d, miR-181c, and miR-130a. Methods The miRNAs miR-181d, miR-181c, and miR-130a were selected from our group’s prior study by the large-scale microarray analysis technique. In this work, the expression of these miRNAs in the tumor tissue and plasma of patients with grade I (16 patients), II (16 patients), and III (eight patients) meningiomas was evaluated. Results MiR-181d was overexpressed in both tumor tissue and plasma in the studied groups. The level of expression was higher according to the progression of tumor grade. MiR-181c and miR-130a showed no significant difference in the studied groups in either tumor tissue or plasma. Conclusions MiR-181d has potential as a biomarker for meningiomas and is associated with the tumor progression of meningiomas.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The Role of MicroRNA 181d as a Possible Biomarker Associated With Tumor Progression in Meningiomas

Carneiro¹,

Cirino²,

Panepucci³

et al. 2021

Cureus

View full text Add to dashboard Cite

show abstract

“…Thus, the miRNA regulatory network is far-reaching [21]. Previous studies have veri ed that miRNAs are important small regulatory ncRNA molecules that control a fairly large number of biological processes; their important functions have generated interest in their use as biomarkers and their roles as regulators of ageing [21,60] and a number of cancer types [61][62][63]. Recent studies have also suggested that miRNAs are involved in the regulation of age-associated processes and pathologies in multiple mammalian tissues, including the brain, heart, bones, and muscles [21,[64][65][66].…”

Section: Discussionmentioning

confidence: 99%

Age-related ceRNA networks and the mRNA/protein correlation in Drosophila ageing

Yang¹,

Yuán²,

He³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background As Drosophila is a classic model organism, understanding of the regulatory networks has great significance in revealing the genetic mechanisms of ageing and human diseases. Competing endogenous RNA (ceRNA)-mediated regulation is an important mechanism of circular RNA (circRNA) and long non-coding RNA (lncRNA) regulation in ageing and age-related disease. However, extensive analyses of the multi-omics (circRNA/miRNA/mRNA, lncRNA/miRNA/mRNA, and mRNA/protein) characteristics of adult Drosophila ageing have not been reported. Our results determine the ceRNA networks and the mRNA/protein correlations of key differentially expressed genes in adult Drosophila aging, and provide a solid foundation for understanding mechanisms of human ageing and ageing-related diseases. Results Here, differentially expressed circRNAs and microRNAs (miRNAs) between 7 and 42 day old Drosophila were screened and identified. Then, the differentially expressed mRNAs, circRNAs, miRNAs, lncRNAs, and proteins between day 7 and day 42 were used to analyse fly age-related circRNA/miRNA/mRNA and lncRNA/miRNA/mRNA networks and the mRNA/protein correlation in Drosophila ageing. Several key ceRNA networks were identified, such as the circ_0006913/miR-985-3p/Abl, circ_0009500/miR-14-5p/SERCA, XLOC_100429/miR-14-5p/SERCA, and XLOC_100429/miR-14-5p/Vha100-4 networks. Subsequently, 16 pairs of differentially expressed interacting mRNAs/proteins were found, including 10 pairs with the same expression trends and 6 pairs with the opposite expression trends. Furthermore, real-time quantitative PCR (qPCR) was used to verify the expression level of those genes. Conclusions The discovery of these ceRNA networks and the mRNA/protein correlations in adult Drosophila ageing will provide new information for research on human ageing and age-related disease.

show abstract

“…Hence, a higher requirement for clinical management is warranted. It is well documented that the best way to improve the prognosis of brain tumor patients is via total tumor resection [ 2 ]. However, tumors at advanced stages or malignant tumors could be challenging to excise.…”

Section: Introductionmentioning

confidence: 99%

The role of gut microbiota in patients with benign and malignant brain tumors: a pilot study

et al. 2022

View full text Add to dashboard Cite

Gut microbiota is associated with the growth of various tumors, including malignant gliomas, through the brain-gut axis. Moreover, the gut microbiota in patients with malignant tumors may considerably differ from those with benign tumors. However, the associations of gut microbiota with benign and malignant brain tumors remain unclear. Hence, in order to explore these underlying relationships, patients with benign meningioma (n = 32), malignant glioma (n = 27), and healthy individuals (n = 41) were selected to participate in this study. The results showed that the diversity of the microbial ecosystem in brain tumor patients were less than the healthy controls, while no significant differences were observed between the meningioma and glioma groups. The microbial composition also differed significantly between individuals with brain tumors and healthy participants. In meningioma group, pathogenic bacteria like Enterobacteriaceae were increased , whereas certain carcinogenic bacteria were overrepresented in the glioma group, including Fusobacterium and Akkermansia . Furthermore, benign and malignant brain tumor patients lacked SCFA-producing probiotics. Thus , a microbial biomarker panel including Fusobacterium, Akkermansia, Escherichia/Shigella, Lachnospira, Agathobacter , and Bifidobacterium was established. Diagnostic models confirmed that this panel could distinguish between brain tumor patients and healthy patients. Additionally, gut microbiota can affect the differentiation and proliferation of brain tumors via several metabolic pathways based on annotations from the Kyoto Encyclopedia of Genes and Genomes (KEGG). This is the first study designed to investigate whether gut microbiota differs between benign and malignant brain tumor patients, and our work concluded that intestinal flora is a valuable tool for the diagnosis and treatment of brain tumors.

show abstract

The biological and diagnostic roles of MicroRNAs in meningiomas

Cited by 18 publications

References 70 publications

The Role of MicroRNA 181d as a Possible Biomarker Associated With Tumor Progression in Meningiomas

The Role of MicroRNA 181d as a Possible Biomarker Associated With Tumor Progression in Meningiomas

Age-related ceRNA networks and the mRNA/protein correlation in Drosophila ageing

The role of gut microbiota in patients with benign and malignant brain tumors: a pilot study

Contact Info

Product

Resources

About